Stock Events

Stock Events

Xenetic Biosciences 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3XB0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is involved in gene editing, a field that overlaps with Xenetic's work on drug delivery and biosciences, making them direct competitors in the biotech innovation space.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine operates in the genome editing sector, directly competing with Xenetic Biosciences in the development of gene therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is a leading company in CRISPR/Cas9 technology for genome editing, competing in the same biotech and gene therapy space as Xenetic.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics focuses on genomic medicine, including gene editing and therapy, positioning it as a competitor in the same innovative biotech field as Xenetic.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, potentially competing with Xenetic in the rare disease market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing in the broader biotech space for novel drug delivery systems like Xenetic.
Beam Therapeutics
BEAM
Mkt Cap2.51B
Beam Therapeutics specializes in precision genetic medicines through base editing, a form of gene editing competing with Xenetic's bioscience approaches.
Voyager Therapeutics
VYGR
Mkt Cap236.01M
Voyager Therapeutics focuses on the development of gene therapies for neurodegenerative diseases, potentially competing with Xenetic in gene therapy delivery technologies.

About

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Show more...
CEO
Mr. James F. Parslow
Employees
2
Country
US
ISIN
US9840156023

Listings

STU
DE
3XB0.STU
BOATS
BOATS
XBIO.BOATS
XNAS
US
XBIO

0 Comments

Share your thoughts

FAQ

What is Xenetic Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xenetic Biosciences stocks are traded under the ticker 3XB0.STU.
How many employees does Xenetic Biosciences have?▼
As of April 10, 2026, the company has 2 employees.
In which sector is Xenetic Biosciences located?▼
Xenetic Biosciences operates in the Health Care sector.
When did Xenetic Biosciences complete a stock split?▼
Xenetic Biosciences has not had any recent stock splits.
Where is Xenetic Biosciences headquartered?▼
Xenetic Biosciences is headquartered in Framingham, US.